Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Roche Holding Ltd (OP: RHHVF )

248.64 +4.50 (+1.84%)
Streaming Delayed Price Updated: 12:43 PM EDT, May 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roche Holding Ltd

< Previous 1 2 3 4 5 6 7 Next >
Rebound In COVID-19 Tests Lift Roche's Half-Year Sales, Oncology Still Hit By Biosimilars, Pandemic
Roche Holding AG's (OTC: RHHBY) 1H 2021 sales increased by 8% Y/Y at constant exchange rates (CER) to CHF 30.7 billion as peak demand for COVID-19 tests helped... 
Via Benzinga
Exposures COVID-19
Spark Therapeutics' Hemophilia Gene Therapy Achieve Stable, Durable FVIII Expression
Spark Therapeutics, a unit of Roche Holdings AG (OTC: RHHBY), has announced updated data from the ongoing Phase 1/2 trial of SPK-8011 gene therapy in... 
Via Benzinga
AbbVie - Roche's Venclexta Receives Breakthrough Therapy Tag In High-Risk Myelodysplastic Syndromes
The FDA has granted Breakthrough Therapy Designation (BTD) to Venclexta (venetoclax) combined with azacitidine for the potential treatment of adult patients with... 
Via Benzinga
Exposures Product Safety
Roche Unveils New Hemlibra Data Reinforcing Safety Profile In Hemophilia A
According to Roche Holding AG's (OTC: RHHBY) Genentech division, new data from a phase 3b study reinforces the safety profile of blockbuster hemophilia A... 
Via Benzinga
Celldex Stock Surges As It Touts Early-Stage Skin Disease Study Win For CDX-0159
Celldex Therapeutics Inc (NASDAQ: CLDX) got a boost Friday with a data readout from Phase 1b trial of CDX-0159 in patients with antihistamine refractory cold... 
Via Benzinga
WHO Recommends IL-6 Drugs From Sanofi, Roche For Critically-Ill COVID-19 Patients
The World Health Organization (WHO) has endorsed Interleukin-6 (IL-6) receptor antagonists combined with corticosteroids to treat severe COVID-19 cases. Patients... 
Via Benzinga
Exposures COVID-19
Atea Pharma's AT-527 Rapidly Reduces Viral Load Levels In Hospitalized COVID-19 Patients
Atea Pharmaceuticals Inc (NASDAQ: AVIR) has announced positive interim results from a Phase 2 study evaluating AT-527 in hospitalized patients with mild-to-... 
Via Benzinga
Exposures COVID-19
Novartis Claims It Overpaid Genentech $210M In Patent Licensing Pact
Novartis AG (NYSE: NVS) said it dutifully paid millions to Genentech as part of a patent licensing deal dated back to 2005. But now, Novartis discovered it... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Exelixis Shares Drop On Mixed Results For Cabometyx Combo In Early Liver Cancer
Exelixis Inc (NASDAQ: EXEL) and Ipsen (OTC: IPSEY) have announced mixed interim results from the COSMIC-312 Phase 3 trial evaluating cabozantinib (... 
Via Benzinga
Roche's Enspryng Wins European Approval For Spinal Cord, Optic Nerve Inflammation Disorder
The European Commission has approved Roche Holding AG's (OTC: RHHBY) injectable Enspryng for adults and adolescents with neuromyelitis optica spectrum disorder... 
Via Benzinga
FDA Gives Emergency Use Nod For Roche's Arthritis Drug Against Severe COVID-19
The 
Via Benzinga
Exposures Product Safety
Roche's Alzheimer's Antibody Reduces Associated Biomarkers In Subset Of AD Patients, Study Shows
Experimental anti-amyloid antibodies from Eli Lilly & Co (NYSE: LLY) and Roche Holding AG's (OTC: RHHBY) failed to improve symptoms of Alzheimer's... 
Via Benzinga
Roche's New COVID-19 Point Of Care Test Scores FDA Emergency Use Nod
The FDA has granted Emergency Use Authorization (EUA) to Roche Holding AG's (OTC: RHHBY) Cobas SARS-CoV-2 Nucleic acid test for use on the Cobas Liat... 
Via Benzinga
Exposures COVID-19 Product Safety
Amneal's Avastin-Referred Biosimilar Under FDA Review For Colorectal Cancer
The FDA has accepted for review Amneal Pharmaceuticals Inc's (NYSE: AMRX) marketing application seeking approval for Bevacizumab, under Section 351(k) pathway... 
Via Benzinga
Exposures Product Safety
Synlogic, Roche Ink Research Pact For Inflammatory Bowel Disease Therapy
Synlogic Inc (NASDAQ: SYBX) has entered into a research collaboration agreement with Roche Holding AG (OTC: RHHBY) for the discovery of Synthetic Biotic... 
Via Benzinga
Atea Pharma Secures AT-527-Related Milestone Payment Of $50M From Roche
Atea Pharmaceuticals Inc (NASDAQ: AVIR) has achieved a development milestone associated with AT-527 and expects to receive a related payment under its license... 
Via Benzinga
JNJ's Imbruvica, AbbVie's Venclexta Combo Achieves Progression-Free Survival Of 78.4% Versus Gazyva-Chemo Cocktail In Leukemia Patients
A combination of Johnson & Johnson’s (NYSE: JNJ) Imbruvica and AbbVie Inc (NYSE: ABBV) - Roche Holding AG’s (OTC: RHHBY) Venclexta/... 
Via Benzinga
AbbVie-Roche's Venclexta Shows Progression-Free Survival Of 74% In CLL Patients After Three Years Treatment
Genentech, a unit of Roche Holdings AG (OTC: RHHBY), and its collaborating partner AbbVie Inc (NYSE: ABBV) have announced long-term follow-up data ... 
Via Benzinga
Argenx Regains Global Rights from Johnson & Johnson to Blood Cancer Candidate Cusatuzumab
Johnson & Johnson (NYSE: JNJ) has walked away from a $1.6 billion blood cancer candidate deal with Argenx SE (NASDAQ: ARGX) for the CD70-targeting... 
Via Benzinga
Surface Oncology, Roche Team Up to Develop SRF388 Combo Therapy for Liver Cancer
Surface Oncology (NASDAQ: SURF) has entered into a clinical trial collaboration with Roche Holdings AG (OTC: RHHBY) to evaluate former's SRF388, anti... 
Via Benzinga
Biogen, Bio-Thera's Biosimilar Referencing Tocilizumab Meets Primary Endpoints In Late-Stage Study
Biogen Inc (NASDAQ: BIIB) and China's Bio-Thera Solutions Ltd have announced results from the Phase 3 study of BAT1806, a proposed biosimilar referencing... 
Via Benzinga
AbbVie-Roche Win European Approval for Venclyxto in Newly Diagnosed Acute Myeloid Leukemia
The European Commission has approved AbbVie Inc's (NYSE: ABBV) Venclyxto (venetoclax) for the treatment of adult patients with newly diagnosed acute myeloid... 
Via Benzinga
Pieris Stock Surges on Development Pact with Genentech for Respiratory, Ophthalmology Settings
Pieris Pharmaceuticals Inc (NASDAQ: PIRS) has entered into a multi-program research collaboration and license agreement with Genentech, a unit of ... 
Via Benzinga
Exelixis' Cabometyx, Roche's Tecentriq Combo Achieves 27% ORR in High-Risk Prostate Cancer Patients
Exelixis Inc (NASDAQ: EXEL) has announced results from cohort 6 of the COSMIC-021 Phase 1b trial evaluating Cabometyx (cabozantinib) in combination... 
Via Benzinga
I-Mab Showcases Early Data On Uliledlimab/Atezolizumab Combo In Advanced Cancer Settings
I-Mab (NASDAQ: IMAB) unveiled early results from Phase 1 study evaluating uliledlimab in combination with Roche Holdings AG’s (OTC: RHHBY)... 
Via Benzinga
Roche's Cobas COVID Test Scores EUA For Asymptomatic People
Roche Holdings AG’s (OTC: RHHBY) Cobas SARS-CoV-2 Test has received U.S. authorization for testing individuals without symptoms or reasons to suspect a COVID... 
Via Benzinga
Prothena Receives $60M Milestone Payment After Parkinson's Candidate Moves Forward In Mid-Stage Study With Dosing
Prothena Corporation plc (NASDAQ: PRTA) has dosed the first patient in the Phase 2b PADOVA study evaluating prasinezumab in patients with early... 
Via Benzinga
India Gives Emergency Use Nod To Roche-Regeneron's COVID-19 Antibody Cocktail
Roche Holdings AG (OTCMKTS: RHHBY) has received Emergency Use Authorization in India for its investigational antibody cocktail (casirivimab and imdevimab) for... 
Via Benzinga
Exposures COVID-19
Oncologic Drugs Adcomm Backs Merck's Keytruda, Roche's Tecentriq Accelerated Approvals In Bladder Cancer
The FDA’s Oncologic Drugs Advisory Committee voted 5-3 in favor of keeping Merck & Co’s (NYSE: MRK) Keytruda (pembrolizumab) accelerated approval... 
Via Benzinga
Exposures Product Safety
Atea Pharma Stock Is Trading Higher As AT-527 Study In COVID-19 Moves Forward With Dosing
Atea Pharmaceuticals Inc (NASDAQ: AVIR) has dosed the first patient in the Phase 3 MORNINGSKY trial evaluating AT-527 in mild or moderate COVID-19 patients in... 
Via Benzinga
Exposures COVID-19
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.